157 results about "Peritonitis" patented technology

Provided is a method for treating or preventing peritonitis by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents. Further provided is a method for preventing peritoneal hemorrhage, adhesions and abscesses.

The invention provides, inter alia, automated medical methods and apparatus that test PD effluent in a flow path (e.g., with an APD system or CAPD setup) to detect, for example, the onset of peritonitis, based on optical characteristics of the effluent resolved at cellular scales of distance. For example, according to one aspect of the invention, an APD machine includes, in an effluent flow path, apparatus for early stage peritonitis detection comprising an illumination source and a detector. The source is arranged to illuminate peritoneal effluent in a chamber that forms part of the flow path, and the detector is arranged to detect illuminant scattered by the effluent. The detector detects that reflected or scattered illuminant at a cellular scale of resolution, e.g., on a scale such that separate cellular-sized biological (or other) components in the effluent can be distinguished from one another based on scattering events detected by the detector. According to aspects of the invention, the chamber can utilize a deflector to effect turbulent flow for purposes of cleaning biological and other materials from the chamber walls.

The invention provides, inter alia, automated medical methods and apparatus that test PD effluent in a flow path (e.g., with an APD system or CAPD setup) to detect, for example, the onset of peritonitis, based on optical characteristics of the effluent resolved at cellular scales of distance. For example, according to one aspect of the invention, an APD machine includes, in an effluent flow path, apparatus for early stage peritonitis detection comprising an illumination source and a detector. The source is arranged to illuminate peritoneal effluent in a chamber that forms part of the flow path, and the detector is arranged to detect illuminant scattered by the effluent. The detector detects that reflected or scattered illuminant at a cellular scale of resolution, e.g., on a scale such that separate cellular-sized biological (or other) components in the effluent can be distinguished from one another based on scattering events detected by the detector. Other aspects of the invention provide automated medical testing methods and apparatus that detect the onset of peritonitis and other bodily conditions by testing fluids in the body in vivo, e.g., the patient's peritoneum. Such apparatus and methods utilize a first fiber optic bundle to carry illuminant from a source of the type described above into a bodily organ or cavity, and a second fiber optic bundle to carry illuminant scattered by fluid in that organ or cavity to a detector as described above.

This invention discloses isolated short peptides comprising the amino acid sequence Cys-Glu-Phe-His (CEFH) and analogs thereof as well as compositions comprising CEFH peptides and analogs thereof. The CEFH peptides disclosed herein are effective in mediating the denitration of 3-nitrotyrosines (3-NT) in cellular proteins thereby preventing tissue damage associated with excess nitric oxide (NO) and its reactive species. The CEFH peptides disclosed herein are useful in the treatment of ischemia/reperfusion (I/R) injury of various tissues (e.g., I/R injury of heart muscle associated with heart attack or cardiac surgery, I/R injury of brain tissue associated with stroke, I/R injury of liver tissue, skeletal muscles, etc.), septic shock, anaphylactic shock, neurodegenerative diseases (e.g., Alzheimer's and Parkinson's diseases), neuronal injury, atherosclerosis, diabetes, multiple sclerosis, autoimmune uveitis, pulmonary fibrosis, oobliterative bronchiolitis, bronchopulmonary dysplasia (BPD), amyotrophic lateral sclerosis (ALS), sepsis, inflammatory bowel disease, arthritis, allograft rejection, autoimmune myocarditis, myocardial inflammation, pulmonary granulomatous inflammation, influenza- or HSV-induced pneumonia, chronic cerebral vasospasm, allergic encephalomyelitis, central nervous system (CNS) inflammation, Heliobacterium pylori gastritis, necrotizing entrerocolitis, celliac disease, peritonitis, early prosthesis failure, inclusion body myositis, preeclamptic pregnancies, skin lesions with anaphylactoid purpura, nephrosclerosis, ileitis, leishmaniasis, cancer, and related disorders.

The invention provides, inter alia, automated medical methods and apparatus that test PD effluent in a flow path (e.g., with an APD system or CAPD setup) to detect, for example, the onset of peritonitis, based on optical characteristics of the effluent resolved at cellular scales of distance. For example, according to one aspect of the invention, an APD machine includes, in an effluent flow path, apparatus for early stage peritonitis detection comprising an illumination source and a detector. The source is arranged to illuminate peritoneal effluent in a chamber that forms part of the flow path, and the detector is arranged to detect illuminant scattered by the effluent. The detector detects that reflected or scattered illuminant at a cellular scale of resolution, e.g., on a scale such that separate cellular-sized biological (or other) components in the effluent can be distinguished from one another based on scattering events detected by the detector.

The invention relates to a novel veterinary antibacterial agent and in particular relates to a lauroyl arginine ethyl ester ion pair compound derivative which is prepared from lauroyl arginine ethyl ester LAE and an organic acid through reactions. As a livestock aquatic animal antibacterial agent, the derivative is capable of preventing and treating duckling riemerella anatipestifer diseases caused by riemerella anatipestifer, is capable of treating peritonitis diseases caused by escherichia coli and staphylococcus aureus, is capable of preventing and treating fish septicemia caused by aeromonas sobria, and has remarkably improved prevention and treatment effects when being compared with a conventional LAE veterinary antibacterial agent. The derivative can be completely degraded in human bodies and animal bodies and is small in toxic and side effect, environment drug resistance bacteria caused by residual antibacterial agents discharged into the environment can be avoided, and small adverse environment influence can be caused while an effective antibacterial effect is achieved.

This invention describes an ICE inhibitor prodrug (I) having good bioavailability

Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.

The invention discloses a Chinese medicinal pill preparation for treating tuberculosis pleuritis, peritonitis, empyema and broncho-pleural fistula, which is prepared from 26 kinds of Chinese medicinal herbs including notoginseng, lily bulb, Sichuan fritillary bulb, lepidium seed, selfheal and weeping forsythia through steps of disintegrating, sieving, mixing homogenously, making water pills, and drying at low temperature.

The invention discloses an ultraviolet disinfection box for peritoneal dialysis. The ultraviolet disinfection box comprises a box main body, a lifting handle, a reflective film, an iodophor cap storage bag, a movable box cover, a transparent observing window, a protective cover, an infusion pipeline inserting hole, operating gloves, an anti-dust cover, a fixed clamping sheet, a lamp tube bracket, an ultraviolet lamp tube and a connecting wiring harness. According to the ultraviolet disinfection box for peritoneal dialysis provided by the invention, a patient of peritoneal dialysis can operate the gloves to achieve the butt joint of a peritoneal dialysis liquid catheter in a sealed space which is sterilized under ultraviolet radiation, so that peritonitis, which is caused in the case that external bacteria, viruses and dust enter the peritoneal dialysis liquid catheter, is effectively avoided; and the ultraviolet disinfection box for peritoneal dialysis has the characteristics of being low in cost, good in sterilizing efficiency, and being convenient to observe, operate and carry.

The invention relates to a testing system and related methods for detecting peritonitis or infection in peritoneal dialysate removed from a patient. The testing system can include a fluid sensor apparatus in a fluid line of a peritoneal dialysis cycler through which spent peritoneal dialysate can be pumped. The fluid sensor apparatus can detect one or more markers associated with peritonitis or infection.

The invention belongs to the field of biological medicines. The invention discloses application of NS1619 for inhibiting activation of NLRP3 inflammatory corpuscles. An experiment finds that the NS1619 can inhibit autooligomerization of a NLRP3 protein, thus the activation of the NLRP3 inflammatory corpuscles is specifically inhibited, and maturation and secretion of inflammatory factors IL-1 betaand IL-18 are inhibited. At the same time, the NS1619 can further alleviate peritonitis in vivo induced by NLRP3 inflammatory corpuscle agonist MSU. Therefore, according to application of NS1619 forinhibiting activation of NLRP3 inflammatory corpuscles, the latest insights are provided for the NS1619 to treat the NLRP3 inflammatory corpuscles related inflammatory diseases and preparing drugs fortreatment of related diseases.

The present invention relates to the use of lactic acid bacteria capable of adhering to the mucosa of the intestine and especially colonizing it for the prevention of peritonitis. In particular, the present invention relates to the use of such lactic acid bacteria for the prevention of peritonitis caused by cirrhosis of the liver. Specifically, the present invention relates to a method for preventing peritonitis in a patient in need of such prevention. This method includes administering to the patient a lactic acid bacterium that is capable of adhering to the intestine's mucosa and essentially colonizing it for the preparation of an ingestable carrier. The invention also relates to a peritonitis preventing composition of a lactic acid bacterium that is capable of adhering to the intestine's mucosa and essentially colonizing it for the preparation of an ingestable carrier. The carrier is preferably a food or pharmaceutical composition.

The invention relates to application of disulfiram in preparing drugs for preventing and treating diseases related to NLRP3 inflammasome. During research, phenomena are found that the disulfiram can effectively inhibit activation of the NLRP3 inflammasome and inhibit maturation and secretion of an inflammatory activation signal molecule Caspase-1P20 and an inflammatory cytokine IL-1[beta], accordingly has good prevention and treatment effects on the diseases related to the NLRP3 inflammasome, and especially has significant prevention and treatment effects on peritonitis and gouty arthritis.

The invention relates to soluble powder for treating sensitive bacterial infections of poultry, comprising sodium ampicillin, sulbactam sodium and auxiliary materials. As an antibiotic medicine, the inventive medicament is mainly used to treat body infectious diseases such as perihepatitis, pericarditis, salpingitis, vitelline peritonitis, air sacculitis, enteritis, diarrhea and the like caused by sensitive bacteria such as escherichia coli, salmonella and the like. The sodium ampicillin and sulbactam sodium have compatibility when used together. The soluble powder is used to treat body infectious diseases caused by sensitive bacteria, has good absorption and relatively high safety when orally taken, and is suitable for being popularized in animal husbandry.

The present invention relates to a reliable method of prediction of infectious peritonitis in humans, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum or plasma, and a high level is indicative of the development and the severity of peritonitis, allowing the classification of patients according to risk.